Can a precision molecular tool reverse damage in one of the world’s most common lung diseases?
COPD — the lung disease that slowly robs people of their breath — has long been considered irreversible.
Chronic obstructive pulmonary disease affects hundreds of millions of people worldwide and ranks among the leading causes of death. It progressively destroys the small air sacs in the lungs, making breathing harder over time. Current treatments — inhalers, steroids, supplemental oxygen — manage symptoms but don’t halt the underlying damage. That’s what makes new biological approaches to the disease genuinely significant, even at an early stage.
Researchers reviewed by Fight Aging! are testing a new form of senolytic therapy — treatment that eliminates senescent cells — targeted at lung tissue. Senescent cells are cells that have stopped dividing but refuse to die. Instead, they linger and secrete a cocktail of inflammatory signals that damage nearby tissue. In the lungs of COPD patients, they accumulate in elevated numbers, and strong evidence links them to the progressive decline in lung function that defines the disease.
Hijacking the cell’s own waste system
The new approach employs a class of molecules called PROTACs — Proteolysis-Targeting Chimeras. These engineered molecules work by redirecting the cell’s own protein disposal machinery to destroy specific target proteins. In this context, PROTACs are designed to degrade proteins that help senescent cells survive. Without those survival signals, the senescent cells can no longer persist and are cleared. This is different from earlier senolytics like dasatinib and quercetin, which act more broadly and carry a higher risk of off-target effects.
The potential precision advantage is meaningful: by narrowly defining the molecular target, it may be possible to clear senescent cells in the lungs without harming healthy cells elsewhere. In cell culture models and animal experiments, this approach produced promising results — fewer senescent cells, reduced inflammation, and improved markers of lung tissue health. But translating that success to human COPD patients is rarely straightforward.
The hard limit of structural damage
Even if PROTAC-based senolytics perform exactly as hoped, a fundamental problem remains. In advanced COPD, the structural destruction of lung tissue — the loss of alveoli, the small air sacs responsible for gas exchange — may not be reversible simply by removing senescent cells. The tissue is already gone. Senolytic therapy might slow or stop the decline, but recovering lost lung capacity would likely require additional regenerative approaches, such as stem cell therapy or engineered tissue.
The most realistic scenario may be that senolytics are most valuable early — before large-scale structural damage has occurred. That raises difficult questions about screening and diagnosis. COPD is frequently detected late, when symptoms are already noticeable and damage is substantial. As a preventive intervention in high-risk individuals — smokers, people with genetic susceptibility — senolytics may hold more promise than as a treatment for advanced disease. That question remains unanswered.